bluebird bio Inc.

3.86+0.0200+0.52%Vol 3.36M1Y Perf -49.80%
Nov 29th, 2023 16:00 DELAYED
BID3.83 ASK3.90
Open3.89 Previous Close3.84
Pre-Market3.90 After-Market-
 0.04 1.04%  - -
Target Price
6.88 
Analyst Rating
Moderate Buy 2.52
Potential %
78.24 
Finscreener Ranking
     29.44
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
     30.74
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
     26.91
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
22.11 
Earnings Rating
Strong Buy
Market Cap422.04M 
Earnings Date
7th Nov 2023
Alpha-0.05 Standard Deviation0.19
Beta0.91 

Today's Price Range

3.844.05

52W Range

2.528.58

5 Year PE Ratio Range

-7.30-3.50

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
1.85%
1 Month
36.88%
3 Months
3.21%
6 Months
16.62%
1 Year
-49.80%
3 Years
-91.25%
5 Years
-96.86%
10 Years
-81.10%

TickerPriceChg.Chg.%
BLUE3.860.02000.52
AAPL189.37-1.0300-0.54
GOOG136.40-2.2200-1.60
MSFT378.85-3.8500-1.01
XOM102.34-1.5600-1.50
WFC43.780.41000.95
JNJ152.110.48000.32
FB196.640.99000.51
GE118.860.01000.01
JPM154.320.78000.51
Financial StrengthValueIndustryS&P 500US Markets
1.20
1.30
0.60
1.75
-
Leverage Ratio 2.70
ProfitabilityValueIndustryS&P 500US Markets
-235.30
-8 604.10
-8 486.30
-2 442.70
-
RevenueValueIndustryS&P 500US Markets
3.53M
0.04
-46.11
-0.13
Earnings HistoryEstimateReportedSurprise %
Q03 2023-0.69-0.664.35
Q02 2023-0.72-0.676.94
Q01 2023-0.540.21138.89
Q04 2022-0.45-0.57-26.67
Q03 2022-1.28-0.9228.12
Q02 2022-1.31-1.291.53
Q01 2022-1.26-1.66-31.75
Q04 2021-1.82-1.820.00
Earnings Per EndEstimateRevision %Trend
12/2023 QR-0.6319.23Positive
12/2023 FY-1.8310.29Positive
3/2024 QR-0.3540.68Positive
12/2024 FY-1.867.00Positive
Next Report Date-
Estimated EPS Next Report-0.69
Estimates Count8
EPS Growth Next 5 Years %-
Volume Overview
Volume3.36M
Shares Outstanding109.34K
Shares Float107.04M
Trades Count19.16K
Dollar Volume13.12M
Avg. Volume3.57M
Avg. Weekly Volume3.26M
Avg. Monthly Volume4.03M
Avg. Quarterly Volume3.42M

bluebird bio Inc. (NASDAQ: BLUE) stock closed at 3.86 per share at the end of the most recent trading day (a 0.52% change compared to the prior day closing price) with a volume of 3.36M shares and market capitalization of 422.04M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 1213 people. bluebird bio Inc. CEO is Nick Leschly.

The one-year performance of bluebird bio Inc. stock is -49.8%, while year-to-date (YTD) performance is -44.22%. BLUE stock has a five-year performance of -96.86%. Its 52-week range is between 2.52 and 8.58, which gives BLUE stock a 52-week price range ratio of 22.11%

bluebird bio Inc. currently has a PE ratio of -1.30, a price-to-book (PB) ratio of 4.10, a price-to-sale (PS) ratio of 176.89, a price to cashflow ratio of 5.70, a PEG ratio of -0.02, a ROA of -54.85%, a ROC of -61.02% and a ROE of -101.27%. The company’s profit margin is -%, its EBITDA margin is -8 486.30%, and its revenue ttm is $3.53 Million , which makes it $0.04 revenue per share.

Of the last four earnings reports from bluebird bio Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.69 for the next earnings report. bluebird bio Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for bluebird bio Inc. is Moderate Buy (2.52), with a target price of $6.88, which is +78.24% compared to the current price. The earnings rating for bluebird bio Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

bluebird bio Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

bluebird bio Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 22.27, ATR14 : 0.29, CCI20 : 119.54, Chaikin Money Flow : 0.05, MACD : 0.22, Money Flow Index : 42.80, ROC : 27.18, RSI : 62.13, STOCH (14,3) : 79.23, STOCH RSI : 0.64, UO : 52.38, Williams %R : -20.77), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of bluebird bio Inc. in the last 12-months were: Andrew Obenshain (Sold 3 178 shares of value $24 802 ), Colvin Richard A. (Sold 557 shares of value $4 345 ), Klima Thomas (Sold 4 130 shares of value $14 455 ), Leschly Nick (Sold 4 290 shares of value $33 462 ), Nick Leschly (Sold 4 290 shares of value $33 480 ), Obenshain Andrew (Sold 3 178 shares of value $24 788 ), Richard A. Colvin (Sold 557 shares of value $4 347 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
4 (30.77 %)
4 (30.77 %)
4 (36.36 %)
Moderate Buy
1 (7.69 %)
1 (7.69 %)
1 (9.09 %)
Hold
6 (46.15 %)
6 (46.15 %)
5 (45.45 %)
Moderate Sell
1 (7.69 %)
1 (7.69 %)
1 (9.09 %)
Strong Sell
1 (7.69 %)
1 (7.69 %)
0 (0.00 %)
Summary RatingModerate Buy
2.52
Moderate Buy
2.52
Moderate Buy
2.25

bluebird bio Inc.

bluebird bio Inc is a clinical-stage biotechnology company that develops gene therapies for severe genetic and rare diseases. The company's gene therapy procedures aim to genetically modify a patient's cells to fundamentally correct or address the genetic basis underlying a disease. Bluebird's revenue is derived from collaboration arrangements, research fees, license fees, and grant revenue. The company works with industry peers, strategic partners, and nonprofit organizations for the development and commercialization of its product candidates.

CEO: Nick Leschly

Telephone: +1 339 499-9300

Address: 60 Binney Street, Cambridge 02142, MA, US

Number of employees: 1 213

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

57%43%

Bearish Bullish

58%42%

Bearish Bullish

59%41%

 

TipRanks News for BLUE

Sun, 13 Aug 2023 01:46 GMT Bluebird Bio (BLUE) Receives a Hold from RBC Capital

- TipRanks. All rights reserved.

News

Stocktwits